Scarica l'app Stockscreener
169.28
0.05%
0.08
Dopo l'orario di chiusura:
169.28
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Quest Health Review 2025: Services, Pricing, and Reliability - Healthline
JPMorgan Chase & Co. Raises Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Is Quest Diagnostics Stock Outperforming the S&P 500? - MSN
SVP for Diagnostic Services Plewman Patrick covered exercise/tax liability with 162 shares, decreasing direct ownership by 0.77% to 20,988 units (SEC Form 4) - Quantisnow
Is Quest Diagnostics Stock Worth Holding Onto Right Now? - MSN
Nephron Research Downgrades Quest Diagnostics to Hold From Buy, $184 Price Target - Marketscreener.com
Is Quest Diagnostics Stock Outperforming The S&P 500? - Barchart
Truist maintains hold on Quest Diagnostics stock, $182 target By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) and Google Cloud to Transform Healthcare Data with AI - Insider Monkey
DGX Stock Set to Benefit From New Google Cloud Partnership - MSN
Top 8 AI News Updates Investors Shouldn’t Miss - Insider Monkey
What 9 Analyst Ratings Have To Say About Quest Diagnostics - Benzinga
Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance - AlphaStreet
Baird Adjusts Price Target on Quest Diagnostics to $191 From $190, Keeps Outperform Rating - Marketscreener.com
Quest Diagnostics' (NYSE:DGX) Dividend Will Be Increased To $0.80 - Yahoo Finance
Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock - Investing.com
Quest Diagnostics SVP Michael Prevoznik sells $789,310 in stock By Investing.com - Investing.com Canada
Quest Diagnostics falls on Q1 outlook headwinds, reaffirms FY guidance - MSN
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - TradingView
Quest Diagnostics (DGX) Unveils Strategic Plans at Investor Day - GuruFocus.com
Quest Diagnostics stock falls on Q1 headwinds (DGX:NYSE) - Seeking Alpha
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day - Quantisnow
Quest Diagnostics projects steady growth beyond 2025 - Investing.com India
Quest Diagnostics Lowers Q1 Outlook, Reaffirms 2025 Guidance -March 19, 2025 at 08:42 am EDT - Marketscreener.com
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day – Company AnnouncementFT.com - Financial Times
Quest Diagnostics (NYSE:DGX) Leverages Google Cloud AI For Enhanced Patient Experience - Simply Wall St
Quest Diagnostics Revolutionizes Lab Testing With Google Cloud AI Partnership - StockTitan
Baird Adjusts Price Target on Quest Diagnostics to $190 From $189, Maintains Outperform Rating - Marketscreener.com
Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023 - GuruFocus.com
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX) - Barchart
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
SBI Securities Co. Ltd. Takes Position in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Catherine T. Doherty Sells 5,370 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock By Investing.com - Investing.com Australia
Mutual of America Capital Management LLC Decreases Stake in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock - Investing.com India
Quest Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Citigroup Downgrades Quest Diagnostics (NYSE:DGX) to Neutral - Defense World
Quest Diagnostics EVP sells $125,865 in stock - Investing.com
Quest Diagnostics EVP sells $125,865 in stock By Investing.com - Investing.com South Africa
SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 2,871 shares and was granted 4,434 shares, increasing direct ownership by 14% to 13,119 units (SEC Form 4) - Quantisnow
Labcorp Gains Citi Upgrade While Quest Diagnostics Faces Downgrade On Margin Concerns — Retail Sentiment Mixed - MSN
Quest Diagnostics Incorporated : Your health comes first -March 04, 2025 at 10:54 pm EST - Marketscreener.com
The Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts - Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Citigroup Downgrades Quest Diagnostics to Neutral From Buy, Price Target is $185 -March 04, 2025 at 05:37 am EST - Marketscreener.com
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):